EXEL - Exelixis, Inc.
| Previous close | 21.48 |
| Open | 21.50 |
| Bid | 0.00 x 3200 |
| Ask | 0.00 x 800 |
| Day's range | 21.08 - 21.51 |
| 52-week range | 15.02 - 25.31 |
| Volume | 2,297,769 |
| Avg. volume | 3,262,596 |
| Market cap | 6.408B |
| Beta (5Y monthly) | 1.61 |
| PE ratio (TTM) | 10.78 |
| EPS (TTM) | 1.96 |
| Earnings date | 24 Feb 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 25.00 |
- Zacks
Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?
Investors are looking forward to Cabometyx's performance and pipeline updates, when Exelixis (EXEL) reports Q4 results.
- Simply Wall St.
The Exelixis (NASDAQ:EXEL) Share Price Has Soared 689%, Delighting Many Shareholders
Buying shares in the best businesses can build meaningful wealth for you and your family. While not every stock...
- Business Wire
Exelixis to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 25, 2020
Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2019 financial results will be released on Tuesday, February 25, 2020 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.
- Zacks
Exelixis (EXEL) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Exelixis (EXEL) closed at $19.39, marking a +0.94% move from the previous day.
- Business Wire
Exelixis Announces Encouraging Results for Cabozantinib in Combination With Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Exelixis, Inc. (NASDAQ:EXEL) today announced encouraging results from the metastatic castration-resistant prostate cancer (CRPC) cohort of COSMIC-021, the phase 1b trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with locally advanced or metastatic solid tumors. The data will be presented on Thursday, February 13th during Poster Session A: Prostate Cancer at 11:30 a.m. – 1:00 p.m. PT and 5:30 – 6:30 p.m. PT at the 2020 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU 2020), which is being held in San Francisco, California, February 13 – 15, 2020.
- Zacks
Exelixis (EXEL) Gains But Lags Market: What You Should Know
In the latest trading session, Exelixis (EXEL) closed at $17.60, marking a +0.69% move from the previous day.
- Business Wire
Exelixis Announces Partner Takeda Files New Drug Application in Japan for CABOMETYX® (cabozantinib) for Advanced Hepatocellular Carcinoma
Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX® (cabozantinib) in Japan, has applied to the Japanese Ministry of Health, Labor and Welfare (MHLW) for Manufacturing and Marketing Approval of cabozantinib as a treatment for patients with unresectable hepatocellular carcinoma (HCC) that had progressed after prior systemic therapy.
- Zacks
Roche Submits Application for Tecentriq-Avastin Combo in HCC
Roche (RHHBY) submits sBLA for the label expansion of the Tecentriq-Avastin combo to treat HCC patients who have not received prior systemic therapy.
- Business Wire
Exelixis Announces Results for Combination of Cabozantinib and Nivolumab With or Without Ipilimumab in Advanced Hepatocellular Carcinoma
Exelixis, Inc. (NASDAQ: EXEL) today announced phase 1/2 clinical trial results from the combination of cabozantinib (CABOMETYX®) and nivolumab (Opdivo®) with or without ipilimumab (Yervoy®) in advanced hepatocellular carcinoma (HCC). Data from the cabozantinib combination cohort of the CheckMate 040 trial will be presented on Friday, January 24 during Rapid Abstract Session B from 7:00 – 7:45 a.m. PT at the 2020 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI), which is being held in San Francisco, California, January 23-25, 2020. The data will also be included in Poster Session B from 12:00 – 1:30 p.m. PT and 4:30 – 5:30 p.m. PT on January 24.
- Zacks
GILD or EXEL: Which Is the Better Value Stock Right Now?
GILD vs. EXEL: Which Stock Is the Better Value Option?
- Simply Wall St.
Does Exelixis, Inc. (NASDAQ:EXEL) Have A Good P/E Ratio?
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll show how you can use...
- Zacks
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Business Wire
Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance
Exelixis, Inc. (Nasdaq: EXEL) today announced its key priorities and anticipated milestones for 2020-21, including generating top-line data from key clinical trials, completing enrollment of ongoing studies, initiating new pivotal trials, and progressing its mid-stage and early pipeline. The company intends to make appropriate investments to maximize the clinical development opportunities for CABOMETYX® (cabozantinib), which Exelixis believes could lead to as many as four additional approved indications by year-end 2021, while concurrently working to advance a pipeline of potential new Exelixis medicines through internal drug discovery and business development.
- Zacks
Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data
A low-key week for the biotech sector, with a few pipeline and regulatory updates.
- Zacks
Exelixis to Expand Prostate Cancer Cohort of Cabometyx Study
Exelixis (EXEL) plans to further expand the metastatic CRPC cohort of the phase Ib study on lead drug, Cabometyx.
- Business Wire
Exelixis to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020
Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the 38th Annual J.P. Morgan Healthcare Conference being held next week in San Francisco. Exelixis’ presentation has been scheduled for Tuesday, January 14, 2020 at 7:30 PM EST / 4:30 PM PST.
- Business Wire
Exelixis Further Expands Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Exelixis, Inc. (NASDAQ: EXEL) today announced that based on continued encouraging efficacy and safety data, the company plans to further expand the metastatic castration-resistant prostate cancer (CRPC) cohort of COSMIC-021, the phase 1b trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with locally advanced or metastatic solid tumors. The cohort, which was previously expanded from 30 to 80 patients in July 2019, will now include up to 130 patients.
- Zacks
Roche's (RHHBY) Tecentriq Combo Succeeds in Melanoma Study
Roche's (RHHBY) Tecentriq in combination with Cotellic and Zelboraf meets primary goal.
- Simply Wall St.
How Should Investors React To Exelixis, Inc.'s (NASDAQ:EXEL) CEO Pay?
Michael Morrissey became the CEO of Exelixis, Inc. (NASDAQ:EXEL) in 2010. This analysis aims first to contrast CEO...
